Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

MLA

Bugelski, P. J., et al. “Preclinical Development of Keliximab, a Primatized Anti-CD4 Monoclonal Antibody, in Human CD4 Transgenic Mice: Characterization of the Model and Safety Studies.” Human & Experimental Toxicology, vol. 19, no. 4, Apr. 2000, pp. 230–43. EBSCOhost, https://doi.org/10.1191/096032700678815783.

APA

Bugelski, P. J., Herzyk, D. J., Rehm, S., Harmsen, A. G., Gore, E. V., Williams, D. M., Maleeff, B. E., Badger, A. M., Truneh, A., O’Brien, S. R., Macia, R. A., Wier, P. J., Morgan, D. G., & Hart, T. K. (2000). Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Human & Experimental Toxicology, 19(4), 230–243. https://doi.org/10.1191/096032700678815783

Chicago

Bugelski, P J, D J Herzyk, S Rehm, A G Harmsen, E V Gore, D M Williams, B E Maleeff, et al. 2000. “Preclinical Development of Keliximab, a Primatized Anti-CD4 Monoclonal Antibody, in Human CD4 Transgenic Mice: Characterization of the Model and Safety Studies.” Human & Experimental Toxicology 19 (4): 230–43. doi:10.1191/096032700678815783.